AbCellera (ABCL) Soars 30%+ After Menopause Drug Slashes Hot Flashes 83% in Phase 2

AbCellera Biologics (ABCL) ripped higher Monday, jumping more than 30% to about $9.07, after the biotech reported positive top-line Phase 2 results for its lead candidate, ABCL-635. The non-hormonal therapy cut the frequency of menopause-related hot flashes by 83%, and investors rushed in, driving one of the stock’s biggest single-day gains in years.

Key Points

• The catalyst: ABCL reported positive top-line Phase 2 data for ABCL-635, its non-hormonal treatment for moderate-to-severe vasomotor symptoms (hot flashes) tied to menopause.
• The result: The drug delivered an 83% reduction in hot-flash frequency, along with a favorable tolerability profile.
• The move: Shares surged 30%+ to roughly $9.07 on heavy volume — nearly 30 million shares traded versus a ~7 million average.
• The balance sheet: AbCellera holds more than $500 million in cash, giving it a long runway despite ongoing losses.
• The quarter: Q2 revenue came in light at about $4 million against a net loss near $55 million.
• The momentum: ABCL is now up roughly 165% year-to-date, far outpacing the S&P 500.
• The analyst view: Stifel maintained a Buy rating last week and lifted its price target to $9.

A Clean Clinical Win Ignites the Rally

Because clinical-stage biotechs live and die by trial data, ABCL-635’s strong readout gave investors exactly the catalyst they wanted. The therapy targets vasomotor symptoms without relying on hormones, and that distinction matters: many women either can’t take or prefer to avoid hormone-based treatments. Consequently, an 83% reduction in hot-flash frequency positions AbCellera to compete in a large, underserved market. Moreover, the company paired the efficacy data with a favorable tolerability profile, which strengthens the drug’s commercial case as it advances.

Financials Give the Story Staying Power

Although ABCL remains unprofitable, its balance sheet buys time to develop the pipeline. The company reported more than $500 million in cash, and that cushion lets management fund further trials without immediately tapping the equity market. To be sure, the latest quarter looked soft — revenue landed near $4 million while the net loss ran to roughly $55 million — yet investors clearly prioritized the clinical milestone over near-term income statement noise. In addition, AbCellera runs a broader engine beyond ABCL-635, including partnerships with Eli Lilly, AbbVie, Jazz Pharmaceuticals, and Vertex, so the Phase 2 win adds to an already diversified platform.

The Move in Context

The scale of Monday’s rally underscores how much the data mattered. ABCL had already climbed about 165% year-to-date heading into the announcement, and today’s surge extended that run dramatically. Furthermore, volume exploded to nearly 30 million shares — roughly four times the daily average — which signals genuine conviction rather than a thin, low-liquidity pop. On the Street, sentiment had already been warming: Stifel reiterated a Buy last week and nudged its target to $9, right around where shares now trade.

What to Watch Next

Looking ahead, investors should first track the detailed Phase 2 data and the planned 12-week follow-up, since fuller results will either reinforce or temper today’s enthusiasm. Next, watch for guidance on ABCL-635’s path toward Phase 3 and any timeline management provides for advancing the program. Finally, keep an eye on the partnership pipeline; additional milestones from the Lilly, AbbVie, Jazz, or Vertex collaborations could give AbCellera (ABCL) further catalysts. Ultimately, if the company converts this readout into a clear regulatory roadmap, today’s spike could mark the start of a durable re-rating rather than a one-day event.